Sign in

    Kevin Kuo • B. Riley Securities

    Kevin Kuo is an Equity Research Analyst at B. Riley Securities, specializing in healthcare and biotechnology sector coverage with a focus on clinical-stage therapeutics companies. He has contributed to research on companies such as Cognition Therapeutics and Lineage Cell Therapeutics, providing in-depth analysis for institutional investors. Kuo joined B. Riley in recent years and is active in buy-side conference calls discussing earnings and strategic developments, but does not have public rankings on analyst performance tracking platforms. His background reflects specialized expertise in securities analysis, and he maintains relevant industry credentials required for equity research roles.

    Kevin Kuo's questions to Lineage Cell Therapeutics Inc (LCTX) leadership

    Kevin Kuo's questions to Lineage Cell Therapeutics Inc (LCTX) leadership • Q2 2024

    Question

    Kevin Kuo of B. Riley Securities inquired about the new services agreement with Roche, asking for more detail on how it enhances the partnership and for any updates on the support for commercial manufacturing scale-up.

    Answer

    CEO Brian Culley explained that while confidentiality limits specifics, the timing of the agreement after Roche's pipeline review is a positive indicator. He highlighted that the agreement includes a five-year follow-up extension for Phase I/IIa patients, suggesting partner enthusiasm. Culley confirmed Lineage is compensated for these services and that the technology transfer for manufacturing to Roche/Genentech is a complex, ongoing process, reinforcing Lineage's expertise as a barrier to entry.

    Ask Fintool Equity Research AI